Palmitoyl Tripeptide-1
/ Synthetic palmitoylated tripeptide; INCI 'Palmitoyl Tripeptide-1'; topicalised GHK (palmitoyl-glycyl-histidyl-lysine)ALIAS · Pal-GHK · Biopeptide CL · Palmitoyl Tripeptide-1 (INCI)
Terms in this page you can click for a plain-English popup: , , , , , , , .
Tier 4. Topical palmitoylated form of GHK (glycyl-L-histidyl-L-lysine). The base GHK sequence has its own dedicated Open Assay page covering the underlying matrikine biology (Pickart group, copper-binding chemistry). Palmitoyl Tripeptide-1 is the topical-cosmetic INCI form, marketed under names such as Biopeptide CL.
Palmitoyl Tripeptide-1 is N-terminally palmitoylated GHK. The base GHK tripeptide is a well-characterised matrikine with copper-binding activity and fibroblast-stimulating effects (see the GHK page for Pickart-group primary literature). Palmitoylation increases lipophilicity for topical delivery; the supplier rationale is sustained release of GHK at the dermal layer after esterase-mediated cleavage of the palmitoyl group.
Tier 4 for the cosmetic palmitoylated form specifically. The base GHK sequence has independent peer-reviewed matrikine and copper-peptide literature (cross-referenced on the GHK page); the topical palmitoyl form is documented mainly in supplier dossiers and finished-product cosmetic trials.
No published independent safety database for the palmitoyl form. Cosmetic INCI status implies regulatory acceptance for topical use.
Regulatory status
- FDA status:
- Not FDA-approved
The palmitoyl form's claimed advantage over unconjugated GHK in topical preparations is delivery-driven (better stratum-corneum penetration). Independent comparative penetration and bioequivalence data in human skin are limited. Cross-reference: see the dedicated GHK page on Open Assay for the underlying base-peptide biology.